Find the latest news on lawsuits involving injuries from dangerous prescription drugs.
The FDA warned Actos patients that long-term use of the drug may be associated with bladder cancer. An ongoing study has revealed that people taking the drug for more than one year have an increased risk of developing bladder cancer. The FDA announcement came just days after Germany and France banned sale of the drug.
The FDA has been monitoring Actos for this risk since September 2010 and will continue assessing the safety of the drug.
Byetta was approved by the FDA on April 28, 2015 for treatment of Type II Diabetes. Byetta is an injectable drug intended to allow diabetics to better regulate their blood sugar levels. The injection is administered twice daily and encourages insulin production.
The FDA has issued two safety alerts concerning Byetta. The agency reported in August 2008 that it had reviewed 30 reports of acute pancreatitis in patients taking Byetta. The FDA also asked Amylin Pharmaceuticals to add stronger and more prominent warnings to the label advising patients about the risk of pancreatitis. Two studies have demonstrated a link between Byetta and pancreatitis, which often leads to the development of pancreatic cancer.
The Federal Food and Drug Administration (FDA) warned of serious skin reactions associated with Onfi (clobazam) and announced labeling changes reflecting these side effects. The FDA reported that people taking Onfi are at risk of developing Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
The incidence of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis is most prevalent during the first eight week of treatment or when the medication is stopped and then resumed. The labeling for FDA has been changed to identify these serious side effects.
A settlement reached with Boehringer Ingelheim, the German company that manufactures Pradaxa, will settle approximately 4,000 state and federal lawsuits for $650 million. The settlement averages $162,500 per claimaint.
The lawsuits alleged that use of Pradaxa could cause serious bleeding events, sometimes resulting in death. In fact, the FDA reports that in 2011 alone more than 540 patients lost their lives after using Pradaxa. This surpassed all other monitored drugs for the year.
Testosterone therapy medications have been approved by the federal Food and Drug Administration (FDA) for treatment of men who have been diagnosed with hypogonadism, a medical condition in which the body fails to produce adequate levels of testosterone.
Medical research reveals that men who use testosterone drugs are at a substantially greater risk of heart attack, stroke and death than are men who do not use the Low-T therapies. Pending lawsuits against drug manufacturers allege, among others, that manufacturers failed to properly research the potential side effects of testosterone drugs, concealed critical information about their serious side effects, and improperly marketed these drugs to consumers.
Xarelto (rivoroxaban) is a newer generation anticoagulant/blood thinner prescribed to treat atrial fibrillation (abnormal heart rhythm) and to reduce the risk of stroke and prevent blood clots in patients following hip and knee implant surgeries. Unfortunately, Xarelto use has been linked to uncontrollable internal bleeding and other serious side effects.